(Q40929413)

English

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

scientific article published on 30 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1 reference

ChEBI release 2020-05-28

drug interaction

0 references

author name string

Erik Mogalian

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Polina German

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Brian P Kearney

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Cheng Yong Yang

4

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Diana Brainard

5

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

John McNally

6

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Lisa Moorehead

7

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Anita Mathias

8

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

publication date

30 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

605-613

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

The global health burden of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Characterization of cell lines carrying self-replicating hepatitis C virus RNAs

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: methods and application

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Membrane transporters in drug development

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

The drug efflux-metabolism alliance: biochemical aspects.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Induction of phase I, II and III drug metabolism/transport by xenobiotics

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0334-7

21 January 2018

Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design

1 reference

https://pubmed.ncbi.nlm.nih.gov/26519191

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships

1 reference

https://pubmed.ncbi.nlm.nih.gov/26519191

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus

1 reference

https://pubmed.ncbi.nlm.nih.gov/26519191

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transporters in drug development: advancing on the Critical Path

1 reference

https://pubmed.ncbi.nlm.nih.gov/26519191

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic theory of cassette dosing in drug discovery screening

1 reference

https://pubmed.ncbi.nlm.nih.gov/26519191

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/26519191

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-015-0334-7

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40929413&oldid=2204102016"